GSK claims broader 'tissue-agnostic' label for PD-1 drug Jem...

The FDA has approved GlaxoSmithKline's latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the patient population eligible for treatment with the drug.

Failed trial nixes another FDA approval, this time for BMS' ...

Bristol-Myers Squibb's HDAC inhibitor Istodax has been on the US market for a decade as a treatment for peripheral T-cell lymphoma (PTCL), but will now be withdrawn from sale after a failed

BMS claims first EU okay for adjuvant oesophageal cancer imm...

Bristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy market, and has just reinforced its position with an EU approval in t

BMS pulls speedy Opdivo approval for liver cancer in US

Bristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for hepatocellular carcinoma, a common form of liver cancer,

The key to psoriasis innovation? Dispelling the shadow of th...

Look out BMS, Cytokinetics has its eye on mavacamten's turf

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ma